TCTR20230208004尚未招募1 期
A Bioequivalence Study of Two Formulations of 25 mg Pregabalin Capsules in Healthy Thai Volunteers under Fasting Conditions
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1 Thai male or female, age between 18 to 55 years
- •2 Has body mass index (BMI) between 18.0 to30.0
- •3 Has been determined healthy by physical examination, assessment of medical history and vital signs or showing no clinically significant abnormalities in the opinion of principal investigator or designated physicians
- •4 Has normal or acceptable results for all screening tests
- •5 Has negative result for hepatitis B viral profile
- •6 Has normal or acceptable report for EKG
- •7 Male subjects agree to use effective contraceptive from screening visit to the follow-up visit
- •8 Female subjects must agree not to become pregnant for the entire participation period and must have a negative result for a urine pregnancy test performing at screening and prior to dosing at period 1 and period 2.
- •9 Female subjects who is childbearing potential and using effective non-hormonal contraceptive methods or total abstinence from sexual intercourse from screening visit to the follow-up visit
- •10.Female subject who is non-childbearing potential hysterectomy, both ovaries removed, surgically sterilized or postmenopausal for
- •11.Non-smokers
- •12Refrain from using herbal medications, dietary supplements within 14 days before the first administration of study drug. Subjects must agree to refrain from these items until the last collection time-point of period 2
- •13Subjects must have ended the systematic medications at least 30 days prior to Day 1 and agree to continue their refraining throughout the follow-up period
- •14Subject dose not receive Coronavirus Disease-19 vaccine within 14 days before dosing and does not plan to receive COVID-19 vaccine until the follow-up visit
- •15Subjects must refrain from drinking caffeine and alcohol for at least 72 hours prior to Day 1 and agree to continue their refraining throughout the last collection time-point of period 2
- •16Has ability and intention to comply with the requirements of study and available for the whole study period
- •17 Willing to participate and voluntarily signed the informed consent form prior to the initiation of any screening or study specific procedure
排除标准
- •1 Known hypersensitivity to pregabalin and/or related structure and/or its constituents
- •2 Has history or concurrent symptoms of cardiovascular, gastrointestinal, hematological disorders, renal and hepatic impairment and/or any disease that may affect the bioavailability of the drug
- •3 Alcohol abuse or excessive use in the last 12 months
- •4 Alcohol breath test at screening visit or before admission show alcohol concentration more than 0
- •5 History of drug abuse or urine sample at screening visit or before admission shows a positive test for Morphine, Marijuana and Methamphetamine
- •6 Following a special diet
- •7 A pregnant woman or woman in breast feeding period
- •8 A woman of childbearing potential and using hormonal contraceptive methods including oral contraceptives, hormone replacement therapy and transdermal contraceptives within 14 days prior to dosing and during the entire period of the study and/or using injected, intrauterine and implanted hormonal methods of contraception within 3 months prior to dosing and during the entire period of the study
- •9 A participant in any investigation drug study within last 30 days prior to screening
- •10 Has blood donated within last 2 months
研究者
相似试验
尚未招募
1 期
A Bioequivalence Study of Two Formulations of 25-mg Empagliflozin Tablets in Healthy Thai Volunteers under Fasting ConditionsHealthy Thai VolunteersTCTR20221003003Siriraj Institute of Clinical Research (SICRES)28
Unknown
1 期
A Bioequivalence Study of Two Formulations of 50-mg Vildagliptin Tablets in Healthy Thai Subjects under Fasting ConditionsAntidiabeticVildagliptin, BioequivalenceTCTR20220613003T.O. Chemicals (1979) Ltd.32
尚未招募
1 期
A Bioequivalence Study of Two Formulations of 50-mg Mirabegron Prolonged Release Tablets in Healthy Thai Volunteers under Fed ConditionsOveractive bladder syndromeOveractive bladder syndrome OABTCTR20220223006ovartis (Thailand) Ltd.44
尚未招募
1 期
A Bioequivalence Study of Two Formulations of 50-mg Mirabegron Prolonged Release Tablets in Healthy Thai Volunteers under Fasting ConditionsOveractive bladder syndromeOABTCTR20220223005ovartis (Thailand) Ltd.54
尚未招募
1 期
A Bioequivalence Study of Dabigatran Etexilate Capsules under Fasting ConditionsPrevention of venous thromboembolism (VTE) in adult patients who have undergone elective hip or knee replacement surgery, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), prevention of recurrent DVT and PE, and prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF)Bioequivalence, Dabigatran, Dabigatran etexilate, generic dabigatran, generic dabigatran etexilate, pharmacokineticsTCTR20210819001MSN Laboratories Private Limited42